Share This Article:

New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography

Abstract Full-Text HTML Download Download as PDF (Size:200KB) PP. 11-13
DOI: 10.4236/mc.2012.12003    4,144 Downloads   8,079 Views   Citations

ABSTRACT

A 64-year-old woman with IgA kappa multiple myeloma was treated with thalidomide-dexa- methasone. Due to progression of the disease, bortezomib, doxorubicin and dexamethasone were administered, followed by autologous stem cell transplantation. Although near-complete remission was achieved, 5 months later, neuro- logical symptoms appeared and the patient was diagnosed with multiple myeloma with cells in- filtrating the spinal cord. Bis-chloronitrosourea, bortezomib and lenalidomide were then admin- istered and although the patient remained neu- rologically asymptomatic, she died 3 months later becausee of disease progression. Lena- lidomide entered into the cerebrospinal fluid (confirmed by ultrasensitive high-performance liquid chromatography), although did not im- prove the poor prognosis of multiple myeloma involving the central nervous system.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Rapado, I., Lahuerta, J., Montejano, L., Montalbán, M., Pares, L. and López, J. (2012) New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography. Modern Chemotherapy, 1, 11-13. doi: 10.4236/mc.2012.12003.

References

[1] Fassas, A.B., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., et al. (2002) Myeloma of the central nervous system: Association with high-risk chro- mosomal abnormalities, plasmablastic morphology, and extramedullary manifestations. British Journal of Hae- matology, 117, 103-108. doi:10.1046/j.1365-2141.2002.03401.x
[2] Chang, H., Bartlett, S.E., Patterson, B., Chen, I.C. and Long, Y.Q. (2005) The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Bri- tish Journal of Haematology, 129, 539-541. doi:10.1111/j.1365-2141.2005.05493.x
[3] Nieuwenhuizen, L. and Biesma, D.H. (2008) Central nervous system myelomatosis: Review of the literature. European Journal of Haematology, 80, 1-9.
[4] Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freed- man, V.H., Stirling, D., et al. (2002) Use of IMDi3, a tha- lidomide analog, as an adjunct to therapy for experiment- tal tuberculous meningitis. Antimicrobial Agents and Chemo- therapy, 46, 1887-1895. doi:10.1128/AAC.46.6.1887-1895.2002
[5] Varettoni, M., Corso, A., Zappasodi, P., Calliada, F., Castagnola, C., Mangiacavalli, S., et al. (2008) Infiltra- tion of the spinal cord in a patient with multiple myeloma. Journal of Clinical Oncology, 26, 4207-4209.
[6] Dimopoulos, M.A. and Kastritis, E. The role of novel drugs in multiple myeloma. Annals of Oncology, 19, 121- 127. doi:10.1093/annonc/mdn444
[7] Serefhanoglu, S., Haznedaroglu, I.C., Goker, H., Buyuka- sik, Y. and Ozcebe, O.I. (2009) Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. Onkologie, 32, 662-664.
[8] Colagrande, M., Di Ianni, M., Ciurnelli, R., Gallucci, M., Mariani, G. and Tabilio, A. (2007) Striking response to intrathecal liposomal cytarabine in a patient with men- ingeal myelomatosis. British Journal of Haematology, 138, 812- 823. doi:10.1111/j.1365-2141.2007.06712.x
[9] Richardson, P.G., Schlossman, R.L., Weller, E., Hide- shima, T., Mitsiades, C., Davies, F., et al. (2002) Immu- nomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067. doi:10.1182/blood-2002-03-0996
[10] Dahut, W.L., Aragon-Ching, J.B., Woo, S., Tohnya, T.M., Gulley, J.L., Arlen, P.M., et al. (2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. The Journal of Clinical Pharmacology, 49, 650- 660. doi:10.1177/0091270009335001

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.